Navigation Links
VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Date:8/1/2008

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress taking place August 4-7 in Boston, MA.

The presentation details are as follows:

Date/Time: Wednesday, August 6, 2008: 2:20-2:50 p.m. ET

Location: World Trade Center Boston & Seaport Hotel

Session: Translational Medicine IV: Case Studies of Translational

Approaches from Preclinical to Clinical Proof-of-Concept

Title: Innovative Clinical Trial and Biomarker Approaches To Demonstrate

the Role Of Leukotrienes and 5LO Inhibition in Atherosclerotic Disease

"VIA has taken an innovative approach in its design of Phase 2 clinical trials for VIA-2291, its lead compound," said Dr. Taub. "I am excited to share with conference participants our view on the value of innovative techniques in the design of critical clinical trials, particularly with regards to serum inflammatory biomarkers, analyses of atherosclerotic plaque tissue, and non-invasive imaging."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
2. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
3. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
5. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
8. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
9. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... cuvette manufacturers is their supercharged customer service and their extensive database of glass cuvette ... of inside information, they have recently revamped their manufacturing techniques to reduce lead times ...
(Date:2/3/2016)... , Feb. 3, 2016  With the growing ... cliff that is underway, therapies such as monoclonal ... a whole host of indications are in high ... in the development and production of these therapeutics. ... quality and high costs, novel approaches and novel ...
(Date:2/3/2016)... BRUNSWICK, N.J. , Feb. 3, 2016 /PRNewswire-USNewswire/ ... grants totaling more than $1 million for researchers ... are working on health-related research that demonstrates exciting ... this round of funding for the New Jersey ... for faculty members at these educational institutions— Princeton ...
Breaking Biology Technology:
(Date:2/3/2016)... -- Vigilant Solutions announces today that the ... solved two recent hit-and-run cases with the ... Solutions. Brian Wenberg explains, "I was ... out of a convenience store and witnessed an elderly male back out ... his vehicle and leaving the scene.  In his statement ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces ... personality, Joey Fatone . Las Vegas , ... --> Las Vegas , where Joey appeared ... The new video ad was filmed at the Consumer Electronics Show ... the Wocket booth to meet and greet fans. ...
Breaking Biology News(10 mins):